The Dermatology Digest

JANUARY 22, 2025

for review for the topical treatment of scalp and body psoriasis in patients aged 12 and up. Safety and Tolerability:Roflumilast foam was well tolerated across studies, with treatment-emergent adverse events (TEAEs) predominantly mild to moderate in severity. for the treatment of seborrheic dermatitis in patients 9 and older.

Dermatitis 36

Dermatitis Safety Treatments Dermatology 36

The Dermatology Digest

JANUARY 10, 2025

is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CAGE Bio, Inc. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 74

Safety Dermatitis Treatments 74

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

MARCH 21, 2025

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

APRIL 18, 2025

James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.

Dermatitis 36

Dermatitis Treatments Safety 36

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. Food and Drug Administration for the treatment of AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

Dermatology Times

FEBRUARY 24, 2025

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

Dermatitis 36

Dermatitis Treatments Safety Management 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. in seborrheic dermatitis. in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Dermatology Times

MARCH 3, 2025

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Dermatitis 36

Dermatitis Treatments Safety Management 36

Dermatology Times

FEBRUARY 24, 2025

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

Dermatitis 36

Dermatitis Treatments Safety 36

Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Food and Drug Administration (FDA) approved topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis.

Dermatitis 72

Dermatitis Office Dermatology Safety 72

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Dermatology Times

FEBRUARY 17, 2025

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

Dermatology Times

JUNE 12, 2024

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dermatitis 36

Dermatitis Treatments Safety 36

The Dermatology Digest

SEPTEMBER 26, 2024

Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. The safety profile was consistent with that previously reported, the study showed. Safety is not an issue.

Dermatitis 74

Dermatitis Safety Management Eczema 74

Dermatology Times

APRIL 25, 2025

Alexandra Golant, MD discusses how the availability of topical ruxolitinib data in children as young as age 2 could potentially shift pediatric atopic dermatitis treatment guidelines by providing a non-steroidal alternative with a favorable safety profile.

Dermatitis 36

Dermatitis Safety Treatments 36

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

FEBRUARY 10, 2025

In patients with moderate-to-severe AD, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication. ” The post AD Pipeline Watch: U.S.

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis.

Dermatitis 74

Dermatitis Office Management Eczema 74

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

Dermatology Times

FEBRUARY 24, 2025

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Dermatitis 36

Dermatitis Safety Therapy Management 36

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

Dermatology Times

JULY 8, 2024

Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.

Dermatitis 36

Dermatitis Safety Management Treatments 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 16, 2023

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 9, 2023

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

DECEMBER 24, 2024

A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations. (..)

Dermatitis 36

Dermatitis Safety Medical Treatments 36

Dermatology Times

MARCH 3, 2025

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Dermatitis 36

Dermatitis Therapy Safety Treatments 36

Dermatology Times

JULY 10, 2024

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36